You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: December 2019 to November 2025

AbstractFullPdf
Dec 2019550
Jan 202018182
Feb 202017170
Mar 202036367
Apr 202018184
May 2020292914
Jun 2020212119
Jul 202013131
Aug 202026268
Sep 2020393936
Oct 2020373715
Nov 202032338
Dec 2020292918
Jan 2021484815
Feb 2021484812
Mar 202130308
Apr 2021242414
May 2021272716
Jun 202161618
Jul 2021494821
Aug 2021353515
Sep 2021424219
Oct 2021242430
Nov 2021252420
Dec 2021383854
Jan 2022282911
Feb 2022383816
Mar 2022353721
Apr 2022353416
May 2022323219
Jun 2022403923
Jul 2022283311
Aug 2022505014
Sep 2022403916
Oct 2022393916
Nov 2022323522
Dec 2022272715
Jan 2023272712
Feb 2023303111
Mar 2023424315
Apr 2023151512
May 2023232310
Jun 202312128
Jul 2023343427
Aug 202320207
Sep 202329299
Oct 202332329
Nov 2023444715
Dec 2023424313
Jan 2024434215
Feb 2024494914
Mar 2024313126
Apr 2024181910
May 202418205
Jun 2024262717
Jul 2024515122
Aug 2024192012
Sep 2024292921
Oct 2024272728
Nov 2024262815
Dec 2024242413
Jan 2025363618
Feb 2025303019
Mar 2025212122
Apr 2025676717
May 2025191913
Jun 2025313120
Nov 2025200
Total211221291019